↓ Skip to main content

Magnesium sulfate for treating exacerbations of acute asthma in the emergency department

Overview of attention for article published in Cochrane database of systematic reviews, January 2000
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs
3 blogs
twitter
31 tweeters
facebook
1 Facebook page
googleplus
1 Google+ user

Readers on

mendeley
108 Mendeley
citeulike
3 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Magnesium sulfate for treating exacerbations of acute asthma in the emergency department
Published in
Cochrane database of systematic reviews, January 2000
DOI 10.1002/14651858.cd001490
Pubmed ID
Authors

Brian H Rowe, Jennifer Bretzlaff, Christopher Bourdon, Gary Bota, Sandra Blitz, Carlos A Camargo, Rowe, B H, Bretzlaff, J A, Bourdon, C, Bota, G W, Camargo, C A, Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA Jr, Rowe, Brian H, Bretzlaff, Jennifer, Bourdon, Christopher, Bota, Gary, Blitz, Sandra, Camargo Jr, Carlos A

Abstract

Treatment of acute asthma is based on rapid reversal of bronchospasm and arresting airway inflammation. There is some evidence that intravenous magnesium can provide additional bronchodilation when given in conjunction with standard bronchodilating agents and corticosteroids. No systematic review of this literature has been completed on this topic. To examine the effect of additional intravenous magnesium sulfate in patients with acute asthma managed in the emergency department. Randomised controlled trials were identified from the Cochrane Airways Review Group register. Bibliographies from included studies, known reviews and texts were searched. Primary authors and content experts were contacted. Randomised controlled trials or quasi-randomised trials were eligible for inclusion. Studies were included if patients presented with acute asthma and were treated with IV magnesium sulfate vs placebo. Data were extracted and methodological quality was assessed independently by two reviewers. Missing data were obtained from authors. Seven trials were included (5 adult, 2 pediatric). A total of 665 patients were involved. Patients receiving magnesium sulfate demonstrated non-significant improvements in peak expiratory flow rates when all studies were pooled (weighted mean difference: 29.4 L/min; 95% confidence interval: -3.4 to 62). In studies of people with severe acute asthma, peak expiratory flow rate improved by 52.3 L/min (95% confidence interval: 27 to 77.5). The forced expiratory volume in one second also improved by 9.8 % predicted (95% confidence interval: 3.8 to 15.8). Overall, admission to hospital was not reduced, odds ratio: 0.31 (95% confidence interval: 0.09 to 1.02). In the severe subgroup, admissions were reduced in those receiving magnesium sulfate (odds ratio: 0.10, 95% confidence interval: 0.04 to 0.27). No clinically important changes in vital signs or adverse side effects were reported. Current evidence does not support routine use of intravenous magnesium sulfate in all patients with acute asthma presenting to the emergency department. Magnesium sulfate appears to be safe and beneficial in patients who present with severe acute asthma.

Twitter Demographics

The data shown below were collected from the profiles of 31 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 4%
Korea, Republic of 2 2%
Canada 2 2%
Chile 1 <1%
Mexico 1 <1%
South Africa 1 <1%
Egypt 1 <1%
Japan 1 <1%
Norway 1 <1%
Other 2 2%
Unknown 92 85%

Demographic breakdown

Readers by professional status Count As %
Researcher 24 22%
Other 17 16%
Professor > Associate Professor 14 13%
Student > Master 12 11%
Student > Bachelor 11 10%
Other 30 28%
Readers by discipline Count As %
Medicine and Dentistry 91 84%
Unspecified 5 5%
Nursing and Health Professions 5 5%
Agricultural and Biological Sciences 4 4%
Social Sciences 2 2%
Other 1 <1%

Attention Score in Context

This research output has an Altmetric Attention Score of 47. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 July 2017.
All research outputs
#187,568
of 8,089,912 outputs
Outputs from Cochrane database of systematic reviews
#695
of 8,797 outputs
Outputs of similar age
#3,990
of 251,396 outputs
Outputs of similar age from Cochrane database of systematic reviews
#45
of 566 outputs
Altmetric has tracked 8,089,912 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,797 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,396 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 566 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.